Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1987 and is headquartered in New York, New York.

Period	TotalRevenue
2015-12-31	$1.75M
2016-12-31	$1.99M
2017-12-31	$2.71M
2018-12-31	$3.41M
2019-12-31	$1.58M
2020-12-31	$1.65M
2021-12-31	$3.56M
2022-12-31	$2.72M
2023-12-31	$2.06M
2024-12-31	$37.20M

	A	B	C	D
1	Symbol	Price	Change	Volume
2	DCTH	$9.63	+0.00%	0.29M
3
4
5

Delcath Systems Inc. (DCTH) Revenue History

Revenue Data

Get Delcath Systems Inc. Data in Excel

More DCTH Financial Data